IMMX — Immix Biopharma Share Price
0.000.00%
Last trade - 00:00- $60.44m
- $44.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.3 | ||
| Price to Tang. Book | 6.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -205.64% | ||
| Return on Equity | -111.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 7th, 2014
- Public Since
- December 16th, 2021
- No. of Shareholders
- 28
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 27,852,341
- Address
- 11400 West Olympic Blvd., Suite 200, LOS ANGELES, 90064
- Web
- https://immixbio.com/
- Phone
- +1 3106518041
- Auditors
- Crowe LLP
Upcoming Events for IMMX
Q3 2025 Immix Biopharma Inc Earnings Release
Similar to IMMX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Immix Biopharma share price?
As of Today at 21:14 UTC, shares in Immix Biopharma are trading at $2.17. This share price information is delayed by 15 minutes.
How has the Immix Biopharma share price performed this year?
Shares in Immix Biopharma last closed at $2.17 and the price had moved by +1.88% over the past 365 days. In terms of relative price strength the Immix Biopharma share price has underperformed the S&P500 Index by -9.88% over the past year.
What are the analyst and broker recommendations for Immix Biopharma?
The overall consensus recommendation for Immix Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immix Biopharma dividend yield?
Immix Biopharma does not currently pay a dividend.
Does Immix Biopharma pay a dividend?
Immix Biopharma does not currently pay a dividend.
When does Immix Biopharma next pay dividends?
Immix Biopharma does not currently pay a dividend.
How do I buy Immix Biopharma shares?
To buy shares in Immix Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immix Biopharma?
As of the previous close price of $2.17, shares in Immix Biopharma had a market capitalisation of $60.44m.
Where are Immix Biopharma shares listed?
Here are the trading details for Immix Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMMX
What kind of share is Immix Biopharma?
Based on an overall assessment of its quality, value and momentum Immix Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immix Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Immix Biopharma is $7.00. That is 222.58% above the last closing price of $2.17.
Analysts covering Immix Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreWhat is the trend in the Immix Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immix Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -7.3%.
As of the last closing price of $2.17, shares in Immix Biopharma were trading +14.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immix Biopharma PE Ratio?
The Immix Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immix Biopharma?
We do not have data on Immix Biopharma's directors